Bromazepam

Summary

Bromazepam (CHEMBL277062) is an approved small molecule (ATC N05BA08); indicated across 4 conditions including anxiety and dementia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05BA08
• Indications: 4 conditions
• Clinical trials: 1
• Chemistry: 316.15 Da · C14H10BrN3O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL277062
Name	Bromazepam
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	2441
ATC	N05BA08
Molecular formula	C14H10BrN3O
Molecular weight	316.15
InChIKey	VMIYHDSEFNYJSL-UHFFFAOYSA-N

SMILES: C1C(=O)NC2=C(C=C(C=C2)Br)C(=N1)C3=CC=CC=N3

IUPAC name: 7-bromo-5-pyridin-2-yl-1,3-dihydro-1,4-benzodiazepin-2-one

Also known as: Bromazepam, Bromazepam civ, Lectopam, Lexatin, Lexotan, Lexotanil, NSC-140669, compendium, BROMAZEPAM, bromazepam

Patent coverage: 2,270 distinct patent families (8,627 SureChEMBL compound mentions), from 4 matched compound structure(s). One matched structure accounts for 8,497 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Alpha-1A adrenergic receptor, Gamma-aminobutyric acid receptor subunit alpha-1.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P62813	6.96	AC50	110	nM	CHEMBL_ACT_25130753

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
anxiety	4	MONDO:0011918	EFO:0005230
dementia	3	MONDO:0001627	HP:0000726
depressive disorder	3	MONDO:0002050	MONDO:0002050

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02374567	PHASE3	TERMINATED	Pharmacovigilance in Gerontopsychiatric Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).